Daewon Pharmaceutical Future Growth
Future criteria checks 4/6
Daewon Pharmaceutical is forecast to grow earnings and revenue by 45.8% and 9.4% per annum respectively. EPS is expected to grow by 44.8% per annum. Return on equity is forecast to be 12% in 3 years.
Key information
45.8%
Earnings growth rate
44.8%
EPS growth rate
Pharmaceuticals earnings growth | 31.0% |
Revenue growth rate | 9.4% |
Future return on equity | 12.0% |
Analyst coverage | Low |
Last updated | 08 Jan 2025 |
Recent future growth updates
Recent updates
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) P/E Still Appears To Be Reasonable
Jan 06Daewon Pharmaceutical's (KRX:003220) Conservative Accounting Might Explain Soft Earnings
Nov 22Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Aug 13Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors
Jul 17There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings
Mar 21Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?
Mar 26Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?
Mar 07Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?
Feb 18Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 31Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?
Jan 13Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend
Dec 24Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly
Dec 10Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?
Nov 22Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 728,300 | 47,600 | 14,200 | 65,400 | 1 |
12/31/2025 | 667,300 | 43,400 | 10,800 | 59,800 | 1 |
12/31/2024 | 602,600 | 21,100 | -52,500 | -900 | 1 |
9/30/2024 | 593,945 | 16,019 | -23,103 | 23,974 | N/A |
6/30/2024 | 566,094 | 14,688 | -27,439 | 3,232 | N/A |
3/31/2024 | 561,164 | 23,534 | 13,489 | 35,232 | N/A |
12/31/2023 | 526,952 | 23,917 | 31,124 | 51,734 | N/A |
9/30/2023 | 508,634 | 26,133 | 2,411 | 17,105 | N/A |
6/30/2023 | 501,899 | 31,749 | 18,273 | 30,359 | N/A |
3/31/2023 | 485,917 | 31,071 | 12,267 | 27,176 | N/A |
12/31/2022 | 478,885 | 31,944 | 13,048 | 26,413 | N/A |
9/30/2022 | 457,308 | 34,728 | 32,452 | 47,937 | N/A |
6/30/2022 | 425,588 | 29,928 | 29,070 | 43,137 | N/A |
3/31/2022 | 396,239 | 25,575 | 26,645 | 37,726 | N/A |
12/31/2021 | 354,176 | 6,989 | 10,707 | 22,413 | N/A |
9/30/2021 | 330,686 | 3,431 | -1,072 | 9,864 | N/A |
6/30/2021 | 315,870 | 657 | -2,219 | 10,266 | N/A |
3/31/2021 | 302,889 | 2,120 | -5,196 | 9,803 | N/A |
12/31/2020 | 308,501 | 17,640 | 9,567 | 24,951 | N/A |
9/30/2020 | 318,297 | 24,073 | 17,186 | 32,837 | N/A |
6/30/2020 | 318,091 | 27,037 | 9,738 | 27,081 | N/A |
3/31/2020 | 322,124 | 28,904 | 3,497 | 25,727 | N/A |
12/31/2019 | 317,828 | 27,289 | -5,681 | 30,971 | N/A |
9/30/2019 | 310,802 | 25,085 | -11,697 | 37,498 | N/A |
6/30/2019 | 299,871 | 23,773 | -14,584 | 38,140 | N/A |
3/31/2019 | 291,785 | 22,795 | -16,335 | 32,324 | N/A |
12/31/2018 | 286,653 | 23,744 | -2,550 | 40,032 | N/A |
9/30/2018 | 279,338 | 18,195 | -9,540 | 24,814 | N/A |
6/30/2018 | 279,933 | 21,779 | N/A | 23,703 | N/A |
3/31/2018 | 273,784 | 14,212 | N/A | 22,066 | N/A |
12/31/2017 | 265,462 | 10,742 | N/A | 4,265 | N/A |
9/30/2017 | 258,275 | 14,662 | N/A | 14,033 | N/A |
6/30/2017 | 248,350 | 13,180 | N/A | 12,924 | N/A |
3/31/2017 | 245,490 | 19,632 | N/A | 21,123 | N/A |
12/31/2016 | 240,722 | 20,242 | N/A | 20,792 | N/A |
9/30/2016 | 235,046 | 20,787 | N/A | 19,544 | N/A |
6/30/2016 | 229,691 | 16,712 | N/A | 19,899 | N/A |
3/31/2016 | 222,267 | 17,791 | N/A | 19,164 | N/A |
12/31/2015 | 216,187 | 17,695 | N/A | 25,817 | N/A |
9/30/2015 | 208,270 | 17,453 | N/A | 25,040 | N/A |
6/30/2015 | 201,669 | 19,596 | N/A | 25,604 | N/A |
3/31/2015 | 190,870 | 17,286 | N/A | 21,799 | N/A |
12/31/2014 | 181,985 | 15,729 | N/A | 17,447 | N/A |
9/30/2014 | 174,309 | 14,143 | N/A | 12,782 | N/A |
6/30/2014 | 168,940 | 11,977 | N/A | 12,571 | N/A |
3/31/2014 | 165,717 | 12,625 | N/A | 15,754 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A003220's forecast earnings growth (45.8% per year) is above the savings rate (2.7%).
Earnings vs Market: A003220's earnings (45.8% per year) are forecast to grow faster than the KR market (27.6% per year).
High Growth Earnings: A003220's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: A003220's revenue (9.4% per year) is forecast to grow faster than the KR market (9.2% per year).
High Growth Revenue: A003220's revenue (9.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A003220's Return on Equity is forecast to be low in 3 years time (12%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/01 06:46 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daewon Pharmaceutical Co., Ltd. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
Jae Hoon Shin | Hanwha Investment & Securities Co., Ltd. |
Changhee Woo | IBK Securities Co. Ltd. |